Actifol Tablet 5 mg

Actifol Tablet is a pharmaceutical product containing Folinic Acid (Calcium Folinate) 5 mg, manufactured by ACI Limited. This tablet formulation is primarily used to counteract the toxic effects of folate antagonists like methotrexate and treat folate-deficient megaloblastic anemia.

Priced at ৳9.00 per unit, Actifol offers cost-effective therapy. A strip costs ৳90.00, while a pack of 3×10 tablets is priced at ৳270.00. Proper storage requires temperatures below 30°C, protection from light, and keeping it away from children.

Key medical applications include:

• Neutralizing methotrexate toxicity in rescue therapy.
• Managing megaloblastic anemia caused by folate deficiency.
• Treating nutritional deficiencies during pregnancy or liver diseases.

As a Folinic Acid derivative, it aids DNA synthesis by acting as a cofactor in 1-carbon transfers. Unlike folic acid, it bypasses enzymatic blocks caused by antifolate drugs, making it vital in oncology protocols.

Dosage varies based on use: 15 mg every 6 hours for methotrexate rescue, 5-15 mg daily for anemia. Children’s safety data remain limited. Drug interactions with antiepileptics or fluoropyrimidines require caution due to seizure risks.

Common side effects include mucositis, diarrhea, or leukopenia. Pregnancy use is permitted if benefits outweigh risks, though lactation safety is unconfirmed. Overdose management focuses on symptom relief, as no specific antidote exists.

Methotrexate rescue: 15 mg every 6 hours for 10 doses. Acute toxicity requires equimolar dosing with methotrexate. Megaloblastic anemia: 5-15 mg daily. Pediatric dosing not established. Administered orally as tablets.

The most common side effects of Actifol are mucositis, stomatitis, leukopenia and/or diarrhea, which may be dose-limiting.

Pregnancy Category C: Use after risk-benefit analysis. Lactation safety unknown. Requires physician guidance for folinic acid therapy.

Administer under oncology specialist supervision. Maintain urine pH >7 for methotrexate clearance. Monitor serum methotrexate until <0.1 micromolar concentration achieved.

Pediatric/geriatric dosing not validated. Hepatic/renal impairment requires therapeutic monitoring. Manufactured by ACI Limited.

There have been no reported sequelae in patients who have received significantly more calcium folinate than the recommended dosage. Flowever, excessive amounts of calcium folinate may nullity the chemotherapeutic effect of folic acid antagonists. There is no specific antidote to calcium folinate overdose. In cases of overdosage patients should be given appropriate supportive care.